Physician

Haskell Mcgill Kirkpatrick, MD

According to 2025 Medicare claims, Haskell Kirkpatrick, MD (NPI: 1356384200) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Dallas, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1003083445; TIN: 752131429) and primary practice location at 75231-7001.

Kirkpatrick's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 807 traditional Medicare patients, billed 225,986 HCPCS/CPT codes, and received $3,453,846 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,189 prescription claims across 222 beneficiaries totaling $4,091,192 in drug costs, led by Revlimid (Lenalidomide). DME data shows 26 claims. Open Payments data shows 23 records totaling $702. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,530,296 to $3,453,846. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $973,812 to $4,091,192. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,698 and ending at $4,519.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	477	141,785	$1,530,296
2016	675	143,128	$1,952,864
2017	815	213,007	$2,591,414
2018	857	255,030	$3,764,015
2019	860	298,596	$3,783,750
2020	836	240,169	$3,437,310
2021	796	194,295	$2,760,146
2022	835	203,120	$3,490,275
2023	870	228,839	$3,537,320
2024	807	225,986	$3,453,846

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	177	1,008	$973,812
2016	179	1,007	$1,243,900
2017	183	1,224	$1,670,473
2018	188	1,204	$2,274,490
2019	199	1,154	$2,545,784
2020	212	1,217	$2,286,381
2021	212	1,271	$2,411,579
2022	231	1,281	$2,964,161
2023	222	1,285	$3,186,631
2024	222	1,189	$4,091,192

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	132	$39,157
2016	N/R	80	$16,238
2017	N/R	90	$21,122
2018	13	76	$10,535
2019	N/R	195	$67,362
2020	N/R	254	$85,421
2021	N/R	132	$8,244
2022	N/R	162	$40,426
2023	N/R	76	$12,479
2024	N/R	26	$885

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	186	509	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	243	588	$94
80053	Blood test, comprehensive group of blood chemicals	394	1,259	$10
36415	Insertion of needle into vein for collection of blood sample	408	1,414	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	383	1,269	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	67	1,882	$1,035,710
Tagrisso	Osimertinib Mesylate	38	1,125	$613,860
Brukinsa	Zanubrutinib	41	1,230	$604,589
Alecensa	Alectinib Hcl	25	750	$445,206
Imbruvica	Ibrutinib	13	364	$212,772

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$640
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$702	Kite Pharma, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Haskell Mcgill Kirkpatrick, MD?

Tedicare shows public-source Medicare data for Haskell Mcgill Kirkpatrick, MD (NPI 1356384200), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Haskell Mcgill Kirkpatrick, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Haskell Mcgill Kirkpatrick, MD?

Haskell Mcgill Kirkpatrick, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1003083445) in the available physician profile data.

Does Haskell Mcgill Kirkpatrick, MD have Open Payments data?

Haskell Mcgill Kirkpatrick, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.